Kathryn Alexander is an Equity Capital Markets Consultant advising senior executives of healthcare companies on strategy and investor relations practices. Kathryn has over 20 years of experience in the financial services industry including a decade covering pharmaceutical stocks and several years in asset management. Kathryn helped establish the Leerink Pharmaceutical Fund, which was the first healthcare-focused, public equity fund launched by Leerink Capital Partners, the former asset management subsidiary of Leerink Partners, a healthcare-focused investment bank. Before this, she was a Vice President at the Trout Group providing investor relations counsel to US and European-based healthcare companies. Additionally, Kathryn spent nine years at Leerink Partners in Equity Research as part of the firm’s Major Pharmaceuticals team analyzing large-cap and specialty pharmaceutical companies. Kathryn graduated from Boston College in 1999 with a B.A. in Economics. She is the mother of three children, a passionate advocate for rare disease patients and caregivers, and an Associate Member of the Council for Women of Boston College.
With new and innovative treatments, better clinical and research options and emerging registry options, newborn screening has become an important discussion topic in the rare disease community. This multi-stakeholder panel will talk through the current state and federal landscape of NBS, and then turn to projections on the initiatives that could shape the future of NBS. Hear from patient advocates on the benefits of early screening and diagnosis, and from an industry partner about the work being done to support the addition of conditions to federal and state testing panels.